TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, ... TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. Show more
Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024, at...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.215 | 8.01374819103 | 27.64 | 36.5 | 27.1006 | 6443212 | 31.8715659 | CS |
4 | 5.885 | 24.5515227368 | 23.97 | 36.5 | 22.61 | 4116015 | 27.80535071 | CS |
12 | 5.335 | 21.7577487765 | 24.52 | 36.5 | 21.11 | 3777765 | 25.19651697 | CS |
26 | 11.625 | 63.7685134394 | 18.23 | 36.5 | 15.16 | 3289514 | 22.53977607 | CS |
52 | 18.925 | 173.147301006 | 10.93 | 36.5 | 10.8153 | 3874322 | 18.73384881 | CS |
156 | 1.105 | 3.84347826087 | 28.75 | 36.5 | 3.48 | 3876809 | 14.70369863 | CS |
260 | 21.785 | 269.950433705 | 8.07 | 56.74 | 3.48 | 3020980 | 17.4322208 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.